DJIA 16,262.56 89.32 0.55%
NASDAQ 4,034.16 0.00 0.00%
S&P 500 1,842.98 12.37 0.68%
market minute promo

Cubist Pharmaceuticals

NASDAQ: CBST

63.19 1.53 (2.48%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

CBST $63.19 2.48%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $61.74
Previous Close $61.66
Daily Range $59.13 - $63.59
52-Week Range $44.25 - $82.12
Market Cap $4.7B
P/E Ratio -234.04
Dividend (Yield) $0.00 (0.0%)
Volume 1,436,992
Average Daily Volume 794,229
Current FY EPS $1.86

Sector

Healthcare

Industry

Drugs

Cubist Pharmaceuticals (CBST) Description

A biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Website: http://www.cubist.com/

News & Commentary

This Week in Biotech

Two key FDA actions, two positive late-stage clinical trials, and a late-week billion-dollar merger are among this week's top biotech stories.

Jefferies Stocks to Buy That Could Jump From an Earnings Surprise

Will Johnson & Johnson (JNJ) Miss This Earnings Season? - Analyst Blog

Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst B

Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog

Cubist Pharmaceuticals (CBST) Marked As Today's Roof Leaker Stock

CBST Crosses Below Key Moving Average Level

Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog

Durata Therapeutics: Gains Ahead

Tetraphase Antibiotic Nearing Key Tolerability Test

Cubist Rises on Favorable FDA Panel View - Analyst Blog

Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog

Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog

See More CBST News...

CBST's Top Competitors

CBST $63.19 (2.48%)
Current stock: CBST
AMGN $115.00 (1.48%)
Current stock: AMGN
GILD $68.17 (2.07%)
Current stock: GILD
BIIB $285.49 (2.14%)
Current stock: BIIB